ABBOTT RECEIVES FDA APPROVAL FOR NEW HUMIRA DELIVERY DEVICE

Abbott announced today that the U.S. Food and Drug Administration (FDA) approved the HUMIRA Pen, a new device for administering HUMIRA (adalimumab), a treatment approved for moderate to severe rheumatoid arthritis (RA) and psoriatic arthritis (PsA). With its one-touch activation and easy-to-grasp size and shape, the HUMIRA Pen offers improved ease of use for these patients, many of whom may have swelling or stiffness in the hands.
Abbott Laboratories